Multicenter Real-World Data of Subsequent Chemotherapy after Progression to PARP Inhibitors in a Maintenance Relapse Setting

Article Oncology

Olaparib maintenance monotherapy in platinum-sensitive relapsed ovarian cancer patients without a germline BRCA1/BRCA2 mutation: OPINION primary analysis

A. Poveda et al.

Summary: The OPINION trial investigated the efficacy of olaparib maintenance therapy in patients without deleterious mutations. The results showed clinical benefit in all subgroups.

GYNECOLOGIC ONCOLOGY (2022)

添加到收藏夹

Article Oncology

Second-line olaparib maintenance therapy is associated with poor response to subsequent chemotherapy in BRCA1/2-mutated epithelial ovarian cancer: A multicentre retrospective study

Junsik Park et al.

Summary: This retrospective observational study examined the impact of olaparib on subsequent therapy for recurrent epithelial ovarian cancer. The results showed that patients receiving olaparib maintenance therapy had a poorer response to third-line chemotherapy, suggesting a potential resistance to olaparib.

GYNECOLOGIC ONCOLOGY (2022)

添加到收藏夹

Review Oncology

Preventing and Overcoming Resistance to PARP Inhibitors: A Focus on the Clinical Landscape

Rosario Prados-Carvajal et al.

Summary: PARP inhibitors have revolutionized the treatment of ovarian, breast, pancreatic, and prostate cancers but resistance to these drugs continues to be a challenge. In this review, the mechanisms of resistance to PARP inhibitors are discussed, with a focus on clinically relevant findings and potential strategies to overcome resistance.

CANCERS (2022)

添加到收藏夹

Article Oncology

European cancer mortality predictions for the year 2022 with focus on ovarian cancer

M. Dalmartello et al.

Summary: Cancer mortality rates in Europe have been decreasing over the last three decades. Lung cancer and ovarian cancer rates have decreased, while stomach cancer, colorectal cancer, breast cancer, and prostate cancer rates have shown significant declines. Leukemia and uterine cancer mortality rates have also decreased.

ANNALS OF ONCOLOGY (2022)

添加到收藏夹

Article Oncology

Response to Chemotherapy and Clinical Outcome of Patients With Recurrent Epithelial Ovarian Cancer After PARP Inhibitor Maintenance Treatment: A Multicenter Retrospective Italian Study

Angiolo Gadducci et al.

Summary: This study aimed to evaluate the response rates and survival rates in EOC patients who received PARP inhibitor maintenance and subsequently underwent salvage chemotherapy after PARPi. The results showed that the longer the platinum-free interval, the higher the objective response rates and survival rates after chemotherapy, but these rates were lower than expected.

ANTICANCER RESEARCH (2022)

添加到收藏夹

Article Oncology

Efficacy of subsequent chemotherapy for patients with BRCA1/2-mutated recurrent epithelial ovarian cancer progressing on olaparib versus placebo maintenance: post-hoc analyses of the SOLO2/ENGOT Ov-21 trial

J. S. Frenel et al.

Summary: In the SOLO2 trial, maintenance olaparib showed significant improvement in patients with platinum-sensitive relapsed ovarian cancer (PSROC) and BRCA mutation. However, the efficacy of subsequent chemotherapy after olaparib treatment is still unknown.

ANNALS OF ONCOLOGY (2022)

添加到收藏夹

Article Oncology

A meta-analysis of reversion mutations in BRCA genes identifies signatures of DNA end-joining repair mechanisms driving therapy resistance

L. Tobalina et al.

Summary: Germline mutations in BRCA1 or BRCA2 genes predispose to hereditary breast and ovarian cancer. Tumours from these patients are sensitive to platinum drugs and PARPi treatments. Some patients develop reversion mutations capable of restoring BRCA protein expression, mainly in DNA repair pathways. Identifying and targeting these pathways could improve treatment durability and offer new therapeutic opportunities.

ANNALS OF ONCOLOGY (2021)

添加到收藏夹

Letter Oncology

Updated treatment recommendations for newly diagnosed epithelial ovarian carcinoma from the ESMO Clinical Practice Guidelines

N. Colombo et al.

ANNALS OF ONCOLOGY (2021)

添加到收藏夹

Article Oncology

Combination ATR and PARP Inhibitor (CAPRI): A phase 2 study of ceralasertib plus olaparib in patients with recurrent, platinum-resistant epithelial ovarian cancer

Payal D. Shah et al.

Summary: In platinum-resistant HGSOC patients, the combination therapy of olaparib plus ceralasertib was well-tolerated, with no objective responses observed. However, a signal of activity was seen particularly in diseases associated with BRCA1 mutations. Further evaluation should include alternate dosing strategies in genomically-selected populations.

GYNECOLOGIC ONCOLOGY (2021)

添加到收藏夹

Article Oncology

Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial

Andres Poveda et al.

Summary: Olaparib provided a median overall survival benefit of 12.9 months compared with placebo in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation. Although statistical significance was not reached, these findings are arguably clinically meaningful and support the use of maintenance olaparib in these patients.

LANCET ONCOLOGY (2021)

添加到收藏夹

Meeting Abstract Oncology